EMEA-000118-PIP04-17 - paediatric investigation plan

abatacept
PIP Human

Key facts

Invented name
  • Orencia
  • Orencia
Active substance
abatacept
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0183/2018
PIP number
EMEA-000118-PIP04-17
Pharmaceutical form(s)
  • Powder for concentrate for solution for infusion
  • Solution for injection
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries

Bristol-Myers Squibb Pharma EEIG 
E-mail: medical.information@bms.com 
Tel. +44 (0)1423 533610

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Compliance check done
No

Decision

Share this page